Agonist News and Research

RSS

Three-pronged combination immunotherapy shows promise for pancreatic cancer patients

Giving patients with operable pancreatic cancers a three-pronged combination immunotherapy treatment consisting of the pancreatic cancer vaccine GVAX, the immune checkpoint therapy nivolumab and urelemab, an anti-CD137 agonist antibody treatment, is safe, it increases the amount of cancer-killing immune system T cells in the tumors and it appears effective when given two weeks prior to cancer-removal surgery, according to new research directed by Johns Hopkins investigators.

17 Jul 2023

Stable nanoparticles train the immune system to fight cancer

Over the past decade, researchers have sought more effective and enduring cancer treatments. Among the wide variety of immunotherapies, Stimulator of Interfron Genes activation (STING agonism) has emerged as a particularly promising approach that harnesses a patient’s immune system to combat tumors throughout the body.

17 Jul 2023

The American Journal of Health Economics articles examine policies to address opioid crisis

The August 2023 issue of the American Journal of Health Economics will feature a cluster of articles that examine the opioid crisis.

10 Jul 2023

Research establishes ERβ as a tumor suppressor in inflammatory breast cancer

A new editorial paper was published in Oncotarget's Volume 14 on June 12, 2023, entitled, "ERβ as a mediator of estrogen signaling in inflammatory breast cancer."

3 Jul 2023

New study uncovers effects of beer compound on cartilage cells in osteoarthritis

Formononetin (FNT), an isoflavonoid present in beer, was investigated for its effects on chondrocytes, the cells responsible for joint health. While low levels of FNT showed no harm and reduced inflammation, excessive exposure promoted catabolic responses, shedding light on the relationship between beer consumption and osteoarthritis risk.

3 Jul 2023

TOS members unveil new research about anti-obesity medications at ADA annual meeting

Multiple members of The Obesity Society (TOS) unveiled new research about several anti-obesity medications in development at this year's annual meeting of the American Diabetes Association (ADA) held June 23–26.

29 Jun 2023

Tirzepatide triumphs in significant weight reduction for people with type 2 diabetes

Researchers performed a double-blinded, placebo-controlled phase III randomized clinical trial (RCT).

29 Jun 2023

The Lancet study unveils exciting findings on retatrutide as a novel treatment for type 2 diabetes

Researchers performed a phase II randomized clinical trial (RCT).

29 Jun 2023

Uncovering the hidden genetic connections behind COVID-19 and comorbidities

Researchers performed a protein diffusion network analysis using tissue-specific GRNs to identify predispositions to COVID-19.

21 Jun 2023

Study provides a promising strategy for the treatment of neuroblastoma

Announcing a new publication for Acta Materia Medica journal. Neuroblastoma (NB) is a common solid tumor in children and infants, the formation and regression of which is closely linked to the tumor-host immune relationship.

19 Jun 2023

Common laxative prucalopride may be useful as a pro-cognitive treatment in psychiatric conditions

Cognitive deficits accompany mood disorders and other psychiatric conditions, often with debilitating effects.

13 Jun 2023

New process can help to design drugs with fewer or no side effects

Have you ever wondered how drugs reach their targets and achieve their function within our bodies? If a drug molecule or a ligand is a message, an inbox is typically a receptor in the cell membrane.

7 Jun 2023

Oral semaglutide outperforms other medications in type 2 diabetes treatment, significantly reducing HbA1c and body weight

Orally administered semaglutide shows significant efficacy in reducing HbA1c and body weight in patients with type 2 diabetes compared to other treatments. The study includes a large number of participants from multiple trials.

7 Jun 2023

How does tirzepatide stimulate insulin secretion?

Tirzepatide, a drug approved for diabetes and on the fast track for approval as a weight loss therapy, works through a unique ability to activate two different mechanisms the body uses to control insulin secretion and energy balance, Duke Health researchers report.

6 Jun 2023

Study provides a treasure trove of information on molecular biology of the immune system

Researchers at Sanford Burnham Prebys, collaborating with scientists from Eli Lilly and Company, have revealed the structure and function of a drug called LY3361237, which can reduce the harmful activity of the immune system to help treat autoimmune diseases.

5 Jun 2023

Agonist News and Research

Three-pronged combination immunotherapy shows promise for pancreatic cancer patients

Stable nanoparticles train the immune system to fight cancer

The American Journal of Health Economics articles examine policies to address opioid crisis

Research establishes ERβ as a tumor suppressor in inflammatory breast cancer

New study uncovers effects of beer compound on cartilage cells in osteoarthritis

TOS members unveil new research about anti-obesity medications at ADA annual meeting

Tirzepatide triumphs in significant weight reduction for people with type 2 diabetes

The Lancet study unveils exciting findings on retatrutide as a novel treatment for type 2 diabetes

Uncovering the hidden genetic connections behind COVID-19 and comorbidities

Study provides a promising strategy for the treatment of neuroblastoma

Common laxative prucalopride may be useful as a pro-cognitive treatment in psychiatric conditions

New process can help to design drugs with fewer or no side effects

Oral semaglutide outperforms other medications in type 2 diabetes treatment, significantly reducing HbA1c and body weight

How does tirzepatide stimulate insulin secretion?

Study provides a treasure trove of information on molecular biology of the immune system

Do glucose-lowering medications have different effects on kidney outcomes?

What is the efficacy, safety, and tolerability of novel danuglipron in adults with type two diabetes?

Multicenter, 1-year-long real-world study shows effectiveness of semaglutide for weight loss

Tirzepatide improves body composition across a range of adult age groups, study shows

Insights from experts on the neurobiological processes involved in appetite regulation

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News